SCHEMBL2300130

SCHEMBL2300130

Cc1ccc(F)c(NC(=O)c2ccccc2C(=O)c2ccc3nc(NC(=O)O)[nH]c3c2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 5/20 0.57
▸ BRAF P15056 5/20 0.57
▸ ABL1 P00519 3/20 0.50
▸ KDR P35968 3/20 0.50
▸ LMNA P02545 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ CYP2C9 P11712 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ ABCC4 O15439 1/20 0.50
▸ USP2 O75604 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.49
▸ XIAP P98170 1/20 0.48
▸ MAPT P10636 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ ADORA3 P0DMS8 1/20 0.47
▸ PTGS1 P23219 1/20 0.47
▸ MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299292 0.91 RAF1 (0.55) RAF1BRAFABL1KDRLMNA
SCHEMBL2297867 0.90 RAF1 (0.54) RAF1BRAFABL1KDRLMNA
SCHEMBL2357346 0.86 RAF1 (0.54) RAF1BRAFABL1KDRLMNA
SCHEMBL2358832 0.86 RAF1 (0.54) RAF1BRAFABL1KDRLMNA
SCHEMBL1467172 0.85 NPSR1 (0.46) RAF1BRAFABL1KDRLMNA
SCHEMBL2297881 0.85 RAF1 (0.58) RAF1BRAFABL1KDRLMNA
SCHEMBL2357955 0.83 RAF1 (0.63) RAF1BRAFABL1KDRLMNA
SCHEMBL2301152 0.83 RAF1 (0.57) RAF1BRAFABL1KDRLMNA
SCHEMBL2299028 0.83 RAF1 (0.57) RAF1BRAFABL1KDRLMNA
SCHEMBL2300095 0.82 RAF1 (0.54) RAF1BRAFABL1KDRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 — — EP disclosed
EP-2139483-B1 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-09-18 — — EP disclosed
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 — — US disclosed
Send feedback